MOR Institute Launches Comprehensive Genetic Test to Detect Risks for Dozens of Diseases
The MOR Institute in Israel has introduced a groundbreaking preventive genetic test that identifies potential genetic risks for a wide range of diseases through a single saliva sample. This test screens for mutations in 173 genes linked to significant medical conditions, including hereditary cancers such as breast, ovarian, prostate, colorectal, pancreatic, melanoma, uterine, urinary system, and gastrointestinal cancers. It also detects risks for cardiovascular diseases, clotting disorders, metabolic diseases, monogenic diabetes, eye diseases like glaucoma and retinal disorders, kidney diseases, and sensitivity to anesthesia.
Utilizing advanced genetic sequencing technology, the test is conducted and clinically interpreted at the genomic center laboratory of Beilinson Hospital by expert bioinformaticians and geneticists. It includes all genes deemed highly medically relevant by the American College of Medical Genetics (ACMG) and additional important genes. The test aims to enable early detection and personalized monitoring, prevention, and treatment plans, potentially improving quality of life and reducing morbidity.
For example, identifying a predisposition to colorectal cancer allows for tailored surveillance such as colonoscopies to detect precancerous lesions early. Similarly, recognizing a tendency for excessive blood clotting can lead to simple preventive measures like avoiding smoking or ensuring movement during long flights. The test is intended for generally healthy individuals aged 18 and over and is performed once in a lifetime via an easy saliva swab.
Yoram Segal, CEO of MOR, emphasized the test's role in personalized medicine, stating it is a one-time, innovative service offered by Israel's leading health center network. Dr. Niki Lieberman, MOR's medical director, highlighted the test's power in preventive personalized healthcare, enabling patients and their family doctors to plan individualized screening and reduce disease risks or detect illnesses at very early stages. More information is available on MOR's website or via their call center.
